Cantab Pharmaceuticals Research Ltd, Ribi ImmunoChem Research Inc deal

The companies signed a one-year option covering the use of RIBI's MPL immunostimulant as an adjuvant in a therapeutic vaccine against genital warts. CNTBY is developing recombinant human papillomavirus proteins for a vaccine with potential prophylactic and therapeutic application. ...